NCT01582698CompletedPhase 4
Open-label Phase 4 Study to Investigate the Seropersistence of Tick-borne Encephalitis (TBE) Virus Antibodies From 7 to 10 Years After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 243
- Locations
- 2
- Primary Endpoint
- Seropositivity rate measured by neutralization test (NT) 82, 94, 106 and 118 months after the first booster TBE vaccination administered in the first precursor study and after the booster vaccination in this study
Study Overview
Brief Summary
The purpose of this study is to evaluate TBE antibody persistence from 7 to 10 years after the first booster TBE vaccination with FSME-IMMUN 0.5ml.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 25 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects who participated in the first and second precursor studies will be eligible for participation in this study if:
- •they understand the nature of the study, agree to its provisions and provide written informed consent
- •they received the first booster vaccination with FSME-IMMUN 0.5ml during the first precursor study and did not receive a second booster vaccination in the second precursor study
- •blood was drawn after their first booster vaccination in the first precursor study
Exclusion Criteria
- •Subjects will be excluded from participation in this study if they:
- •received any TBE vaccination since their first booster vaccination with FSME-IMMUN 0.5ml
- •have a history of infection with or vaccination against other flaviviruses (e.g. dengue fever, yellow fever, Japanese B-encephalitis) since their first booster vaccination with FSME-IMMUN 0.5ml
- •are known to be HIV positive since their first booster vaccination with FSME-IMMUN 0.5ml
- •have a known or suspected problem with drug or alcohol abuse
Arms & Interventions
Seropersistence evaluation + 2nd booster vaccination
Experimental
Blood will be drawn to assess the seropersistence of TBE virus antibodies at 82, 94, 106 and 118 months after the first booster vaccination with FSME-IMMUN 0.5ml administered during the first precursor study. Timing of the second booster vaccination will depend on the level of serum TBE antibodies observed during the study. Blood will be drawn 21 - 35 days after vaccination to assess the booster response.
Intervention: FSME-IMMUN 0.5 ml (Biological)
Outcomes
Primary Outcomes
Seropositivity rate measured by neutralization test (NT) 82, 94, 106 and 118 months after the first booster TBE vaccination administered in the first precursor study and after the booster vaccination in this study
Time Frame: 118 months
Secondary Outcomes
- Antibody titers 82, 94, 106 and 118 months after the first booster TBE vaccination administered in the first precursor study and after the booster vaccination in this study measured by ELISA and by NT(118 months)
- Seropositivity rate measured by ELISA test 82, 94, 106 and 118 months after the first booster TBE vaccination administered in the first precursor study and after the booster vaccination in this study(118 months)
- Fold increase in antibody concentration after the booster vaccination administered as compared to before the booster vaccination in this study measured by ELISA and by NT(118 months)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 4
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)Encephalitis, Tick-BorneNCT00503529Pfizer314
Completed
Not Applicable
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in ChildrenEncephalitis, Tick-borneNCT00163618Pfizer
Completed
Phase 4
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)Encephalitis, Tick-BorneNCT00894686Pfizer179
Completed
Phase 3
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary VaccinationInfections, MeningococcalNCT01934140Pfizer311
Completed
Phase 3
The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary VaccinationInfections, MeningococcalNCT01962207Pfizer243